Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial

Published:2023-03 Issue:3 Volume:83 Page:212-221
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Bögemann Martin,Shore Neal D.,Smith Matthew R.,Tammela Teuvo L.J.,Ulys Albertas,Vjaters Egils,Polyakov Sergey,Jievaltas Mindaugas,Luz Murilo,Alekseev Boris,Lebret Thierry,Schostak Martin,Verholen Frank,Le Berre Marie-Aude,Srinivasan Shankar,Ortiz Jorge,Mohamed Ateesha F.,Sarapohja Toni,Fizazi Karim

Publisher

Elsevier BV

Subject

Urology

Reference40 articles.

1. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors;Saad;Prostate Cancer Prostatic Dis,2021

2. Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer;Lavaud;Ther Adv Med Oncol,2020

3. Symptoms and impacts in non-metastatic castration-resistant prostate cancer: qualitative study findings;Tomaszewski;Patient,2017

4. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer;Smith;J Clin Oncol,2005

5. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer;Smith;Cancer,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review;Biomedicines;2024-04-08

2. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS;The Oncologist;2024-02-23

3. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis;Molecular Oncology;2024-01-15

4. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial;European Journal of Cancer;2023-10

5. Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer;Cancers;2023-04-11